The field of ET-1 cancer therapeutics will likely be transformed over the years to come, especially facilitated by the growing knowledge of the genomic features of tumor cells and microenvironments and noninvasively biomarker detection in early stages of cancer. This evidence concerns the gene EDN1 and neoplasm.